Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06898047 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Consistency of Response With Rimegepant in Acute Treatment of Migraine

Study acronym: CORRELATE-UK
StatusActive, Not Recruiting
PhaseNot specified
SponsorPfizer
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Jul 31, 2026 → Oct 31, 2026
See other at-risk trials from Pfizer

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Jul 31, 2026 to Oct 31, 2026
    • Eligibility criteria expanded, about 27 words
    • Secondary endpoints: details revised at 2 of 3 entries
  2. Primary completion pushed from Jun 30, 2026 to Jul 31, 2026
    • Trial arms changed: 1 → 2
    • Secondary endpoints: details revised at 3 of 3 entries
    v9
  3. Re-verified, no change to tracked fieldsv8
  4. Study completion date: Jun 30, 2026 to Jul 31, 2026v7
  5. Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Study sites: 0 to 1
    • Primary and study completion dates: May 29, 2026 to Jun 30, 2026
    • Start date changed from estimate of Sep 17, 2025 to Nov 15, 2025
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Start date: Aug 1, 2025 to Sep 17, 2025
    • Primary and study completion dates: Mar 31, 2026 to May 29, 2026
    v5
  2. Re-verified, no change to tracked fieldsv4
  3. Start date: Apr 2025 to Aug 1, 2025
    • Primary and study completion dates: Sep 15, 2026 to Mar 31, 2026
    v3
  4. Start date: Mar 31, 2025 to Apr 2025v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pfizer
436 trials monitored
See 32 trials at risk
Migraine
482 trials monitored
See 26 trials at risk
This is a non-interventional, prospective study that will enroll participants with migraine in the United Kingdom currently in use of rimegepant to acutely treat migraine attacks. Participants will be followed up for up to 12 weeks and will complete a daily questionnaire to self-report the consistency of response to rimegepant in acute treatment of migraine.
Trial Details
NCT Number NCT06898047
Lead Sponsor Pfizer
Conditions
(from sponsor)		 Migraine
Related terms Migraine Disorders
Enrollment 250 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov